With the continuous growth of Autobio Diagnostics 's regular business, the cost dilution effect has become more and more significant, which has led to an increase in the company's profit margin. From the perspective of financial data, in the first three quarters of this year, Autobio Diagnostics 's sales expense ratio, management expense ratio, and financial expense ratio have declined to varying degrees. At the same time, the company's gross profit margin and net profit margin have slightly increased.

In addition, in the first three quarters of this year, Autobio Diagnostics still maintained a large amount of R&D investment. Financial data shows that in the first three quarters of this year, Antu Bio's R&D expenses were 397 million CNY, a year-on-year increase of 17.50%.

On September 26, Autobio Diagnostics released the "Announcement of the Company and its Subsidiaries Obtaining the Medical Device Registration Certificate". The announcement shows that Autobio Diagnostics and its subsidiaries have received 9 medical device registration certificates issued by the State Drug Administration and the Henan Provincial Drug Administration respectively.

In this regard, Autobio Diagnostics said that the acquisition of the above-mentioned medical device registration certificate has further enriched the company's product menu, continuously met market demand, is an effective supplement to the company's existing testing products, and can gradually improve the overall competitiveness of the company's products.